Aspirin inhibition of n-[4-(5-nitro-2-fury1)-2-thiazolyl]formamideinduced lesions of the urinary bladder correlated with inhibition of metabolism by bladder prostaglandin endoperoxide synthetase

Samuel M. Cohen, Shoji Fukushima, Gen’i Murasaki, Terry V. Zenser, Michael B. Mattammal, Neville S. Rapp, Bernard B. Davis

Research output: Contribution to journalArticle

97 Citations (Scopus)

Abstract

The effects of aspirin on N44-(5-nitro-2-fury1)-2-thiazoly1]- (FANFT) -induced urinary bladder lesions, endogenous bladder prostaglandin E2 synthesis, and the metabolism of FANFT by bladder epithelial microsomes were examined. Rats were fed 0.5% aspirin and/or a diet containing 0.1% or 0.2% FANFT. Bladder lesions were observed with light and scanning electron microscopy, and the prostaglandin E2 content of rat bladder was measured by radioimmunoassay. Metabolism of FANFT was measured by decreased absorbance at 400 nm. Aspirin inhibited the appearance of hyperplastic lesions induced by feeding 0.1% or 0.2% FANFT for 6 or 12 weeks. Aspirin reduced bladder prostaglandin E2 content at 1, 2, 6, and 13 weeks compared to corresponding control values. Rat and rabbit microsomal metabolism of FANFT were dependent upon specific fatty acid substrates and prevented by specific inhibitors (including aspirin) of prostaglandin endoperoxide synthetase. Other inhibitor and substrate specificity studies suggest that FANFT was not metabolized by xanthine oxidase, lipoxygenase, lipid peroxidation, or mixed-function oxidases. These results suggest that the metabolism of FANFT by prostaglandin endoperoxide synthetase may be involved in the metabolic activation of FANFT necessary for the induction of bladder cancer in rats. 9, 2016.

Original languageEnglish (US)
Pages (from-to)3355-3359
Number of pages5
JournalCancer Research
Volume41
StatePublished - Sep 1 1981

Fingerprint

FANFT
Prostaglandin-Endoperoxide Synthases
Aspirin
Urinary Bladder
Dinoprostone
Lipoxygenase
Xanthine Oxidase
Substrate Specificity
Microsomes
Mixed Function Oxygenases
Urinary Bladder Neoplasms
Electron Scanning Microscopy
Lipid Peroxidation
Radioimmunoassay
Fatty Acids

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

Aspirin inhibition of n-[4-(5-nitro-2-fury1)-2-thiazolyl]formamideinduced lesions of the urinary bladder correlated with inhibition of metabolism by bladder prostaglandin endoperoxide synthetase. / Cohen, Samuel M.; Fukushima, Shoji; Murasaki, Gen’i; Zenser, Terry V.; Mattammal, Michael B.; Rapp, Neville S.; Davis, Bernard B.

In: Cancer Research, Vol. 41, 01.09.1981, p. 3355-3359.

Research output: Contribution to journalArticle

Cohen, Samuel M. ; Fukushima, Shoji ; Murasaki, Gen’i ; Zenser, Terry V. ; Mattammal, Michael B. ; Rapp, Neville S. ; Davis, Bernard B. / Aspirin inhibition of n-[4-(5-nitro-2-fury1)-2-thiazolyl]formamideinduced lesions of the urinary bladder correlated with inhibition of metabolism by bladder prostaglandin endoperoxide synthetase. In: Cancer Research. 1981 ; Vol. 41. pp. 3355-3359.
@article{1d77a30fe9e740c180cd6e125de068ae,
title = "Aspirin inhibition of n-[4-(5-nitro-2-fury1)-2-thiazolyl]formamideinduced lesions of the urinary bladder correlated with inhibition of metabolism by bladder prostaglandin endoperoxide synthetase",
abstract = "The effects of aspirin on N44-(5-nitro-2-fury1)-2-thiazoly1]- (FANFT) -induced urinary bladder lesions, endogenous bladder prostaglandin E2 synthesis, and the metabolism of FANFT by bladder epithelial microsomes were examined. Rats were fed 0.5{\%} aspirin and/or a diet containing 0.1{\%} or 0.2{\%} FANFT. Bladder lesions were observed with light and scanning electron microscopy, and the prostaglandin E2 content of rat bladder was measured by radioimmunoassay. Metabolism of FANFT was measured by decreased absorbance at 400 nm. Aspirin inhibited the appearance of hyperplastic lesions induced by feeding 0.1{\%} or 0.2{\%} FANFT for 6 or 12 weeks. Aspirin reduced bladder prostaglandin E2 content at 1, 2, 6, and 13 weeks compared to corresponding control values. Rat and rabbit microsomal metabolism of FANFT were dependent upon specific fatty acid substrates and prevented by specific inhibitors (including aspirin) of prostaglandin endoperoxide synthetase. Other inhibitor and substrate specificity studies suggest that FANFT was not metabolized by xanthine oxidase, lipoxygenase, lipid peroxidation, or mixed-function oxidases. These results suggest that the metabolism of FANFT by prostaglandin endoperoxide synthetase may be involved in the metabolic activation of FANFT necessary for the induction of bladder cancer in rats. 9, 2016.",
author = "Cohen, {Samuel M.} and Shoji Fukushima and Gen’i Murasaki and Zenser, {Terry V.} and Mattammal, {Michael B.} and Rapp, {Neville S.} and Davis, {Bernard B.}",
year = "1981",
month = "9",
day = "1",
language = "English (US)",
volume = "41",
pages = "3355--3359",
journal = "Cancer Research",
issn = "0008-5472",
publisher = "American Association for Cancer Research Inc.",

}

TY - JOUR

T1 - Aspirin inhibition of n-[4-(5-nitro-2-fury1)-2-thiazolyl]formamideinduced lesions of the urinary bladder correlated with inhibition of metabolism by bladder prostaglandin endoperoxide synthetase

AU - Cohen, Samuel M.

AU - Fukushima, Shoji

AU - Murasaki, Gen’i

AU - Zenser, Terry V.

AU - Mattammal, Michael B.

AU - Rapp, Neville S.

AU - Davis, Bernard B.

PY - 1981/9/1

Y1 - 1981/9/1

N2 - The effects of aspirin on N44-(5-nitro-2-fury1)-2-thiazoly1]- (FANFT) -induced urinary bladder lesions, endogenous bladder prostaglandin E2 synthesis, and the metabolism of FANFT by bladder epithelial microsomes were examined. Rats were fed 0.5% aspirin and/or a diet containing 0.1% or 0.2% FANFT. Bladder lesions were observed with light and scanning electron microscopy, and the prostaglandin E2 content of rat bladder was measured by radioimmunoassay. Metabolism of FANFT was measured by decreased absorbance at 400 nm. Aspirin inhibited the appearance of hyperplastic lesions induced by feeding 0.1% or 0.2% FANFT for 6 or 12 weeks. Aspirin reduced bladder prostaglandin E2 content at 1, 2, 6, and 13 weeks compared to corresponding control values. Rat and rabbit microsomal metabolism of FANFT were dependent upon specific fatty acid substrates and prevented by specific inhibitors (including aspirin) of prostaglandin endoperoxide synthetase. Other inhibitor and substrate specificity studies suggest that FANFT was not metabolized by xanthine oxidase, lipoxygenase, lipid peroxidation, or mixed-function oxidases. These results suggest that the metabolism of FANFT by prostaglandin endoperoxide synthetase may be involved in the metabolic activation of FANFT necessary for the induction of bladder cancer in rats. 9, 2016.

AB - The effects of aspirin on N44-(5-nitro-2-fury1)-2-thiazoly1]- (FANFT) -induced urinary bladder lesions, endogenous bladder prostaglandin E2 synthesis, and the metabolism of FANFT by bladder epithelial microsomes were examined. Rats were fed 0.5% aspirin and/or a diet containing 0.1% or 0.2% FANFT. Bladder lesions were observed with light and scanning electron microscopy, and the prostaglandin E2 content of rat bladder was measured by radioimmunoassay. Metabolism of FANFT was measured by decreased absorbance at 400 nm. Aspirin inhibited the appearance of hyperplastic lesions induced by feeding 0.1% or 0.2% FANFT for 6 or 12 weeks. Aspirin reduced bladder prostaglandin E2 content at 1, 2, 6, and 13 weeks compared to corresponding control values. Rat and rabbit microsomal metabolism of FANFT were dependent upon specific fatty acid substrates and prevented by specific inhibitors (including aspirin) of prostaglandin endoperoxide synthetase. Other inhibitor and substrate specificity studies suggest that FANFT was not metabolized by xanthine oxidase, lipoxygenase, lipid peroxidation, or mixed-function oxidases. These results suggest that the metabolism of FANFT by prostaglandin endoperoxide synthetase may be involved in the metabolic activation of FANFT necessary for the induction of bladder cancer in rats. 9, 2016.

UR - http://www.scopus.com/inward/record.url?scp=0019479834&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0019479834&partnerID=8YFLogxK

M3 - Article

C2 - 6790163

AN - SCOPUS:0019479834

VL - 41

SP - 3355

EP - 3359

JO - Cancer Research

JF - Cancer Research

SN - 0008-5472

ER -